GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » Cyclically Adjusted PS Ratio

Apex Biotechnology (TPE:1733) Cyclically Adjusted PS Ratio : 1.51 (As of Jun. 11, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology Cyclically Adjusted PS Ratio?

As of today (2024-06-11), Apex Biotechnology's current share price is NT$33.50. Apex Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was NT$22.19. Apex Biotechnology's Cyclically Adjusted PS Ratio for today is 1.51.

The historical rank and industry rank for Apex Biotechnology's Cyclically Adjusted PS Ratio or its related term are showing as below:

TPE:1733' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.95   Med: 1.23   Max: 1.83
Current: 1.51

During the past years, Apex Biotechnology's highest Cyclically Adjusted PS Ratio was 1.83. The lowest was 0.95. And the median was 1.23.

TPE:1733's Cyclically Adjusted PS Ratio is ranked better than
80.68% of 502 companies
in the Biotechnology industry
Industry Median: 5.43 vs TPE:1733: 1.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Apex Biotechnology's adjusted revenue per share data for the three months ended in Mar. 2024 was NT$4.493. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$22.19 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Apex Biotechnology Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Apex Biotechnology's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology Cyclically Adjusted PS Ratio Chart

Apex Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 1.20 1.25 1.17 1.84

Apex Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.30 1.22 1.84 1.53

Competitive Comparison of Apex Biotechnology's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Apex Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Cyclically Adjusted PS Ratio falls into.



Apex Biotechnology Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Apex Biotechnology's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=33.50/22.19
=1.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Apex Biotechnology's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.493/131.7762*131.7762
=4.493

Current CPI (Mar. 2024) = 131.7762.

Apex Biotechnology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.328 100.560 5.672
201409 4.179 100.428 5.483
201412 4.724 99.070 6.284
201503 4.531 99.621 5.993
201506 4.137 100.684 5.415
201509 4.798 100.392 6.298
201512 4.450 99.792 5.876
201603 4.479 100.470 5.875
201606 4.857 101.688 6.294
201609 3.213 101.861 4.157
201612 3.700 101.863 4.787
201703 4.262 102.862 5.460
201706 4.004 103.349 5.105
201709 4.762 104.136 6.026
201712 3.574 104.011 4.528
201803 4.706 105.290 5.890
201806 4.555 106.317 5.646
201809 4.968 106.507 6.147
201812 4.622 105.998 5.746
201903 4.659 107.251 5.724
201906 5.040 108.070 6.146
201909 4.765 108.329 5.796
201912 5.859 108.420 7.121
202003 4.521 108.902 5.471
202006 4.943 108.767 5.989
202009 4.631 109.815 5.557
202012 4.005 109.897 4.802
202103 5.096 111.754 6.009
202106 4.528 114.631 5.205
202109 5.091 115.734 5.797
202112 5.548 117.630 6.215
202203 5.187 121.301 5.635
202206 6.068 125.017 6.396
202209 6.055 125.227 6.372
202212 5.040 125.222 5.304
202303 4.342 127.348 4.493
202306 4.170 128.729 4.269
202309 4.140 129.860 4.201
202312 4.104 129.419 4.179
202403 4.493 131.776 4.493

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Apex Biotechnology  (TPE:1733) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Apex Biotechnology Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Apex Biotechnology (TPE:1733) Business Description

Traded in Other Exchanges
N/A
Address
No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines